Welcome to our dedicated page for CARDINAL HEALTH SEC filings (Ticker: CAH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cardinal Health, Inc. filings document material events for a healthcare distribution and medical products company, including quarterly results, Regulation FD outlook updates and earnings presentation exhibits. The records tie financial reporting to segment performance, capital returns, debt reduction and corporate finance matters such as revolving credit agreements that support the commercial paper program.
Governance filings cover board composition, annual meeting voting results, director and officer transitions, and related compensation or succession disclosures. The company’s 8-K record also includes material definitive agreements, shareholder voting matters, financial covenants, exhibits and other capital-structure disclosures for Cardinal Health’s public-company profile.
Cardinal Health, Inc. (CAH) is soliciting shareholder votes for its 2026 virtual annual meeting, where investors will elect 11 directors, approve on an advisory basis named executive officer pay, and ratify Ernst & Young LLP as independent auditor for the year ending June 30, 2027.
The proxy details strong fiscal 2026 results, including broad-based profit growth across all five operating segments, double-digit gains in GAAP and non-GAAP operating earnings, and significant increases in operating cash flow and earnings per share. One-year total shareholder return was robust, and three-year return was substantially higher, reflecting execution on strategic priorities in Pharmaceutical and Specialty Solutions, Global Medical Products and Distribution, and growth businesses such as Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics.
The Board highlights an independent Chair structure, committee-only independent membership, enhanced enterprise risk management oversight through the Risk Oversight Committee, and an extensive shareholder engagement program. Recent board refreshment, leadership transitions, and a structured evaluation and education process are emphasized as key elements supporting long-term strategy, risk oversight, and sustainable value creation.
CARDINAL HEALTH INC (CAH) reported that Chief Accounting Officer Mary C. Scherer sold a total of 2,302 Common Shares on 2026-08-19 in open market or private transactions. The sales occurred in two tranches: 100 shares at $237.40 per share and 2,202 shares at $237.39 per share. The filing does not state her share holdings after these transactions, and the Rule 10b5-1 checkbox was left unchecked.
CARDINAL HEALTH INC (CAH) reported that Chief Executive Officer Jason M. Hollar sold an aggregate of 124,529 Common Shares in 10 open-market or private transactions on August 18–19, 2026. The reported weighted average sale prices ranged from approximately $232.75 to $238.07 per share, with each line item reflecting multiple trades within the stated price ranges.
CARDINAL HEALTH INC (CAH) reported that Stephen M. Mason, CEO of the Global Medical Products & Distribution segment, sold a total of 35,000 Common Shares on 2026-08-18 in four open-market transactions. The weighted average sale prices ranged from $234.07 to $237.67 per share, with all shares held directly. The Rule 10b5-1 trading-plan checkbox was not marked as applicable.
CARDINAL HEALTH INC (CAH) executive Deborah Weitzman, CEO of the Pharmaceutical and Specialty Solutions (PSS) segment, reported selling a total of 7,354 Common Shares on August 18, 2026 in three open-market transactions. The sales covered 6,665 shares at a weighted average price of $235.30 (price range $235.17–$236.02), 408 shares at a weighted average price of $236.59 (range $236.24–$237.143), and 281 shares at a weighted average price of $237.44 (range $237.2615–$237.6285). All holdings are reported as directly owned.
CARDINAL HEALTH INC (CAH) reported that Chief Financial Officer Aaron E. Alt sold a total of 42,000 Common Shares on August 18, 2026 in open-market or private transactions. The sales were executed in four blocks at weighted average prices between $234.55 and $237.26, with each price representing a weighted average of multiple trades within stated intraday ranges.
CARDINAL HEALTH INC (CAH) reports that Jessica L. Mayer, Chief Legal/Compliance Officer, sold an aggregate of 29,436 Common Shares on August 18, 2026. The sales occurred in four open market or private transaction tranches at weighted average prices ranging from $234.07 to $237.67 per share.
CARDINAL HEALTH INC (CAH) reported that Chief Information Officer Michelle D. Greene sold a total of 11,650 common shares on August 18, 2026, in multiple open-market or private transactions. The sales were executed in four tranches at weighted average prices of $234.57, $235.68, $236.31, and $237.25 per share, with each weighted average representing numerous individual trades within specified price ranges as disclosed in the footnotes.
CARDINAL HEALTH INC (CAH) officer Mary Scherer filed a notice of proposed sale of Cardinal Health common stock under Rule 144. The filing lists a planned sale of 2,302 shares of common stock through Merrill, with an aggregate market value of $546,461.52 as of August 19, 2026, on the NYSE. The shares to be sold are tied to the scheduled vesting on August 15, 2026 of 844 shares from Restricted Stock and 1,458 shares from Performance Units.